M3 Resultados de beneficios anteriores

Pasado controles de criterios 2/6

M3 ha aumentado sus beneficios a una tasa media anual de 11.6%, mientras que los beneficios de la industria de Healthcare Services han experimentado un crecimiento de 16.3% anual. Los ingresos han ido creciendo a una tasa media de 14% al año. La rentabilidad financiera de M3 es de 11.8%, y sus márgenes netos son de 15.8%.

Información clave

11.6%

Tasa de crecimiento de los beneficios

11.5%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare Services	19.2%
Tasa de crecimiento de los ingresos	14.0%
Rentabilidad financiera	11.8%
Margen neto	15.8%
Última actualización de beneficios	30 Sep 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Earnings Miss: M3, Inc. Missed EPS By 36% And Analysts Are Revising Their Forecasts

Nov 01

Is M3, Inc. (TSE:2413) Potentially Undervalued?

Oct 21

M3, Inc. (TSE:2413) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Oct 06

Return Trends At M3 (TSE:2413) Aren't Appealing

Sep 23

Some M3, Inc. (TSE:2413) Shareholders Look For Exit As Shares Take 26% Pounding

Aug 10

Results: M3, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Jul 30

Desglose de ingresos y gastos

Cómo gana y gasta dinero M3. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

TSE:2413 Ingresos, gastos y beneficios (JPY Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
30 Sep 24	247,907	39,159	74,417
30 Jun 24	245,696	44,105	71,217
31 Mar 24	238,883	45,271	67,647
31 Dec 23	234,852	46,363	66,679
30 Sep 23	233,997	48,374	64,216
30 Jun 23	231,218	49,315	61,685
31 Mar 23	230,818	49,028	58,989
31 Dec 22	229,145	46,955	58,043
30 Sep 22	223,128	47,117	55,378
30 Jun 22	218,752	60,203	53,083
31 Mar 22	208,159	63,845	51,141
31 Dec 21	199,617	67,280	48,151
30 Sep 21	191,823	63,900	46,617
30 Jun 21	180,123	47,124	43,793
31 Mar 21	169,198	37,822	40,906
31 Dec 20	158,404	31,760	36,553
30 Sep 20	144,450	26,520	35,369
30 Jun 20	135,685	23,190	35,158
31 Mar 20	130,973	21,635	35,572
31 Dec 19	125,704	21,589	40,744
30 Sep 19	121,329	20,887	39,102
30 Jun 19	116,927	19,865	37,249
31 Mar 19	113,059	19,577	35,096
31 Dec 18	109,585	19,532	33,192
30 Sep 18	104,897	19,796	30,837
30 Jun 18	99,495	19,580	28,471
31 Mar 18	94,471	19,684	26,320
31 Dec 17	90,402	18,934	24,863
30 Sep 17	86,118	17,830	23,940
30 Jun 17	81,960	17,303	22,784
31 Mar 17	78,143	16,004	21,669
31 Dec 16	73,570	14,871	20,459
30 Sep 16	69,009	13,526	19,407
30 Jun 16	67,189	12,953	18,548
31 Mar 16	64,660	12,508	17,844
31 Dec 15	60,288	11,664	17,206
30 Sep 15	57,241	10,874	16,462
30 Jun 15	54,598	10,486	15,881
31 Mar 15	51,346	9,759	15,234
31 Dec 14	48,687	9,740	14,708
30 Sep 14	44,767	9,236	13,829
30 Jun 14	40,966	8,838	13,097
31 Mar 14	36,887	8,318	12,207
31 Dec 13	33,967	7,409	11,315

Ingresos de calidad: 2413 tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio(15.8%) de 2413 son inferiores a los del año pasado (20.7%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de 2413 han crecido un 11.6% al año en los últimos 5 años.

Acelerando crecimiento: 2413 ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: 2413 tuvo un crecimiento negativo de los beneficios (-19%) durante el año pasado, lo que dificulta la comparación con la media de la industria Healthcare Services (11.1%).

Rentabilidad financiera

Alta ROE: La rentabilidad financiera de 2413 (11.8%) se considera baja.

M3 Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Información clave

Actualizaciones de resultados anteriores recientes

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

M3, Inc. to Report Q2, 2025 Results on Oct 30, 2024

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

M3, Inc. to Report Q1, 2025 Results on Jul 26, 2024

Full year 2024 earnings: EPS misses analyst expectations

M3, Inc. to Report Fiscal Year 2024 Results on Apr 26, 2024

Recent updates

Investor sentiment deteriorates as stock falls 18%

Earnings Miss: M3, Inc. Missed EPS By 36% And Analysts Are Revising Their Forecasts

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

Is M3, Inc. (TSE:2413) Potentially Undervalued?

Investor sentiment improves as stock rises 18%

M3, Inc. (TSE:2413) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Return Trends At M3 (TSE:2413) Aren't Appealing

Price target decreased by 7.2% to JP¥1,834

M3, Inc. to Report Q2, 2025 Results on Oct 30, 2024

Investor sentiment improves as stock rises 20%

Some M3, Inc. (TSE:2413) Shareholders Look For Exit As Shares Take 26% Pounding

Price target decreased by 7.2% to JP¥2,028

Investor sentiment deteriorates as stock falls 19%

Results: M3, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Estimating The Intrinsic Value Of M3, Inc. (TSE:2413)

Is M3 (TSE:2413) Using Too Much Debt?

Now 18% overvalued

Investor Optimism Abounds M3, Inc. (TSE:2413) But Growth Is Lacking

Price target decreased by 9.3% to JP¥2,215

Now 20% overvalued

New minor risk - Share price stability

M3, Inc. to Report Q1, 2025 Results on Jul 26, 2024

M3 (TSE:2413) Will Be Hoping To Turn Its Returns On Capital Around

Price target decreased by 7.4% to JP¥2,263

Full year 2024 earnings: EPS misses analyst expectations

M3, Inc., Annual General Meeting, Jun 26, 2024

Upcoming dividend of JP¥21.00 per share

M3's (TSE:2413) Dividend Will Be Increased To ¥21.00

Dividend increased to JP¥21.00

M3, Inc. to Report Fiscal Year 2024 Results on Apr 26, 2024

Is M3, Inc. (TSE:2413) Worth JP¥2.1k Based On Its Intrinsic Value?

Now 21% overvalued

Price target decreased by 7.9% to JP¥2,762

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 16%

New minor risk - Share price stability

M3, Inc. to Report Q3, 2024 Results on Jan 31, 2024

Price target decreased by 8.7% to JP¥3,000

Price target decreased by 7.7% to JP¥3,158

M3, Inc. (TSE:2413) entered into a share tender agreement to acquire a 55% stake in Benefit One Inc. (TSE:2412) from Pasona Group Inc. (TSE:2168) and others for approximately ¥140 billion.

Price target decreased by 7.3% to JP¥3,241

Price target decreased by 7.1% to JP¥3,422

Second quarter 2024 earnings: EPS exceeds analyst expectations

M3, Inc. Provides Consolidated Earnings Guidance for the Full Fiscal Year Ending March 31, 2024

M3, Inc. to Report Q2, 2024 Results on Oct 27, 2023

M3, Inc. (TSE:2413) acquired Messly Limited.

M3, Inc. (TSE:2413) acquired frogwell corporation.

M3, Inc. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and the Full Year Ending March 31, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

M3, Inc. to Report Q1, 2024 Results on Jul 28, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of JP¥19.00 per share at 0.5% yield

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

M3, Inc. (TSE:2413) acquired Michael Allen Company.

M3, Inc. to Report Q3, 2023 Results on Feb 03, 2023

No independent directors

Second quarter 2023 earnings released: EPS: JP¥18.38 (vs JP¥36.86 in 2Q 2022)

M3, Inc. (TSE:2413) acquired Rinkai Medical Service.

M3, Inc. to Report Q2, 2023 Results on Nov 02, 2022

Investor sentiment improved over the past week

First quarter 2023 earnings released: EPS: JP¥19.87 (vs JP¥23.23 in 1Q 2022)

Investor sentiment improved over the past week

M3, Inc. (TSE:2413) acquired Edoctores Soluciones.

M3, Inc. to Report Q1, 2023 Results on Jul 27, 2022

Price target decreased to JP¥5,358

Full year 2022 earnings: EPS misses analyst expectations

M3, Inc. Announces Dividend for the Year Ended March 31, 2022, Payable on June 13, 2022

No independent directors